Join the Bladder Cancer group to help and get support from people like you.
Bladder Cancer News
Related terms: Cancer, Bladder
FDA Approves Anktiva for BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer
FRIDAY, April 26, 2024 – The U.S. Food and Drug Administration has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients wit...
FDA Approves Anktiva (nogapendekin alfa inbakicept-pmln) Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CULVER CITY, Calif., April 22, 2024 -- ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved Anktiva (N-803, or ...
Urine Test Could Cut Need for Painful Bladder Cancer Procedure
MONDAY, April 8, 2024 – A new urine test could spare bladder cancer survivors from a painful follow-up procedure needed to ensure their cancer hasn’t come back, researchers report. People who’ve got...
Drug Combo Marks Advance Against Bladder Cancer
MONDAY, March 11, 2024 – A cancer drug duo more than doubled the survival of people battling the most common form of advanced bladder cancer, trial results show. Patients who took a combo of meds...
Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Padcev plus pembrolizumab approved based on groundbreaking EV-302 trial Confirmatory trial found Padcev plus pembrolizumab nearly doubled median overall survival compared to standard of care...
Selenium Not Linked to Recurrence of Non-Muscle-Invasive Bladder Cancer
WEDNESDAY, Oct. 18, 2023 – For patients with non-muscle-invasive bladder cancer (NMIBC), selenium supplementation does not reduce the risk for recurrence, while vitamin E is associated with an...
Treatment Strategy Helps People With Advanced Bladder Cancer Retain the Organ
TUESDAY, Oct. 10, 2023 – “Listen, I’m not a Pollyanna,” New Yorker David Cabelis makes clear. “I’m a cab driver.” “But I was diagnosed with this cancer,” the 72-year old said. “Bladder cancer, that’s...
Gemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
WEDNESDAY, Oct. 4, 2023 – For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published...
Urine-Based DNA Methylation Test Can Detect Bladder Cancer
MONDAY, Aug. 21, 2023 – A urine-based DNA methylation test can accurately detect bladder cancer in patients with hematuria, according to a study published online June 14 in The Journal of Molecular...
FDA Approves Adstiladrin (nadofaragene firadenovec-vncg) for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer Efficacy and safety of Adstiladrin supported by...
Genentech Provides Update on Tecentriq U.S. Indication for Previously Untreated Metastatic Bladder Cancer
South San Francisco, CA – November 28th, 2022 -- Genentech, a member of the Roche Group, today announced that the company is voluntarily withdrawing the U.S. indication of Tecentriq® (atezolizumab) f...
FDA Approves Keytruda (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
KENILWORTH, N.J.--(BUSINESS WIRE) January 8, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Padcev (enfortumab vedotin-ejfv) for Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer
TOKYO and BOTHELL, Wash., Dec. 18, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced ...
FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer
April 12, 2019 – The U.S. Food and Drug Administration today granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer...
AstraZeneca’s Imfinzi (durvalumab) Receives FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer
May 1, 2017 – AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi...
Ask a question
To post your own question to this support group, sign in or create an account.